2023-505299-31-00CompletedPhase 1
A Phase I study to evaluate the pharmacokinetics, safety, and tolerability of multiple oral doses of obefazimod in patients with mild and moderate hepatic impairment, compared to matched control groups.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 30 Apr 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- First submitted
- 28 Jun 2023
- Start date
- 9 Oct 2023
- Lead sponsor
- Abivax
- Diseases
- Ulcerative colitis
- EU CT number
- 2023-505299-31-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 32
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CRS Clinical Research Services Management GmbH | Kiel | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.